Cardiometabolic risk reduction by Rimonabant: the effectiveness in daily practice and its use - CARDIO-REDUSE
Phase 1
- Conditions
- Despite therapeutic advances, cardio metabolic disease still remains an important cause of death worldwide. The endocannabinoid system seems to be a new target for multiple risk factor management as it modulates food intake and adipogenesis. Selectively blocking the cannabinoid CB1 receptor with rimonabant has been shown to improve waist circumference, HDL-cholesterol, triglycerides and insulin resistance.
- Registration Number
- EUCTR2006-001404-37-NL
- Lead Sponsor
- Maastricht University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
we aim to include males and females 18 – 70 years of age who have a waist circumference >88 cm in women or >102 cm in men and diabetes mellitus type 2 or an impaired fasting blood glucose > 6.1 mmol/l in venous plasma.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method